Modern biologics manufacturing demands regulatory strategies that keep pace with evolving modalities, data driven controls and continuous processing. This article outlines practical considerations for aligning viral saf...

Since 2024, new guidance from the FDA and EMA has advanced efforts to streamline biosimilar development to enhance commercial appeal for developers. Explore the implications of new regulatory guidance and publications,...

We’re proud to be sponsoring the SOLAR conference taking place on June 25-27. Our hepatology team will be there and looking forward to connecting with others working to advance liver disease research, especially across ...

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our fr...

More than a decade ago, Yordan Zahariev joined ICON as a Clinical Trial Assistant. Today, he leads one of ICON's largest CTA teams in Bulgaria as a Clinical Operations Manager. In our latest career story, Yordan reflect...

Attending CTO East Coast in Boston? Join Padma Varadharajan on 30 June at 9:30am for her core session entitled: “Practical considerations for navigating the landscape of global oncology trials in 2026 and beyond.” This ...

ICON is proud to sponsor the SOLAR conference. Our hepatology specialists will be on-site (25-27 June), talking with peers about the practical side of running liver disease trials from AI-driven site selection to imagi...

Last week, we proudly celebrated a significant milestone, 30 years of ICON Germany. Over the past three decades, our teams in Germany have played an important role in advancing clinical research and supporting customer...

Celebrating 20 years of ICON in Poland. Since our Polish branch was established in Warsaw in 2006, ICON Poland has grown into a team of more than 1,800 employees across Warsaw, Gdańsk, and remote working locations. Ove...

Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...

Access to high-performing sites is a key differentiator for study success. ICON’s premium site network model connects sponsors with experienced, motivated sites, improving enrolment, quality and delivery timelines. Join ...

Implementing digital innovations early in the planning phase is critical to avoiding prolonged vaccine trial cycles. Read the article to learn how AI is helping developers outpace traditional operational hurdles: https:/...